PureTech Health plc (LON: PRTC)
Market Cap | 409.89M |
Revenue (ttm) | 370.31K |
Net Income (ttm) | -65.25M |
Shares Out | 239.42M |
EPS (ttm) | -0.24 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 519,048 |
Open | 160.00 |
Previous Close | 162.00 |
Day's Range | 160.00 - 171.20 |
52-Week Range | 138.75 - 238.50 |
Beta | 1.02 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 28, 2024 |
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the ... [Read more]
Financial Performance
In 2023, PureTech Health's revenue was $3.33 million, a decrease of -78.68% compared to the previous year's $15.62 million. Losses were -$65.70 million, 30.5% more than in 2022.
Financial numbers in USD Financial StatementsNews
CITIGROUP INC Acquires New Stake in PureTech Health PLC
CITIGROUP INC Acquires New Stake in PureTech Health PLC
PureTech to Present at CHEST 2024 Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech to Present at CHEST 2024 Annual Meeting.
PureTech Health plc (PRTC) Q2 2024 Earnings Call Transcript
PureTech Health plc (NASDAQ:NASDAQ:PRTC) Q2 2024 Earnings Conference Call August 28, 2024 9:00 AM ETCompany ParticipantsAllison Mead Talbot - Head of...
PureTech Health plc – Half-Year Report
BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.
PureTech Health: Results of the Tender Offer
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of the Tender Offer.
PureTech Announces Change of Board Role
BOSTON--(BUSINESS WIRE)--Raju Kucherlapati, PhD, has been appointed Chair of the PureTech Board of Directors.
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team.
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of AGM.
PureTech Health: Result of General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Result of General Meeting.
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.
PureTech to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study of VE303.
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
BOSTON--(BUSINESS WIRE)--PureTech Health: Launch of Proposed $100 million Tender Offer at 250 pence per Ordinary Share.
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting.
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments.
PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Conference Call April 25, 2024 9:00 AM ET Company Participants Allison Mead Talbot - Head, Communications Bharatt Chowrira - Chief Executive Officer...
PureTech Announces Annual Results for Year Ended December 31, 2023
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2023.
PureTech Health: Notice of Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
BOSTON--(BUSINESS WIRE)--PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis.
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers.
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
BOSTON--(BUSINESS WIRE)--PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions.
PureTech Health: Repeat What Works
PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's le...
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded...
PureTech to Present at Two Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastat...